Marion Rapp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8302860/publications.pdf

Version: 2024-02-01

75 papers	3,434 citations	236833 25 h-index	143943 57 g-index
76 all docs	76 docs citations	76 times ranked	3880 citing authors

#	Article	IF	Citations
1	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 2009, 27, 5874-5880.	0.8	743
2	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 685-695.	3.3	216
3	Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro-Oncology, 2016, 18, 96-104.	0.6	186
4	Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients. Clinical Cancer Research, 2009, 15, 6683-6693.	3.2	180
5	Diagnostic Performance of ¹⁸F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma. Journal of Nuclear Medicine, 2013, 54, 229-235.	2.8	167
6	Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 22-33.	3.3	158
7	The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology, 2015, 17, 1293-300.	0.6	134
8	Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. Journal of Neuro-Oncology, 2011, 103, 611-618.	1.4	127
9	Role of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. Journal of Nuclear Medicine, 2013, 54, 2046-2054.	2.8	108
10	Glioblastoma Multiforme Metastasis Outside the CNS: Three Case Reports and Possible Mechanisms of Escape. Journal of Clinical Oncology, 2014, 32, e80-e84.	0.8	97
11	DynamicO-(2-¹⁸F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro-Oncology, 2017, 19, now149.	0.6	91
12	Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans. European Radiology, 2017, 27, 2916-2927.	2.3	81
13	Recurrence Pattern Analysis of Primary Glioblastoma. World Neurosurgery, 2017, 103, 733-740.	0.7	76
14	5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression. Oncotarget, 2016, 7, 66776-66789.	0.8	72
15	Proof of principle: supramarginal resection of cerebral metastases in eloquent brain areas. Acta Neurochirurgica, 2012, 154, 1981-1986.	0.9	63
16	DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS. Neurosurgery, 2006, 59, 988-1000.	0.6	61
17	Early postoperative magnet resonance tomography after resection of cerebral metastases. Acta Neurochirurgica, 2015, 157, 1573-1580.	0.9	61
18	5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Acta Neurochirurgica, 2015, 157, 207-214.	0.9	55

#	Article	IF	Citations
19	FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. Cancers, 2020, 12, 3835.	1.7	55
20	Incidence of local in-brain progression after supramarginal resection of cerebral metastases. Acta Neurochirurgica, 2015, 157, 905-911.	0.9	52
21	Endoscopic-Assisted Visualization of 5-Aminolevulinic Acidâ€“Induced Fluorescence in Malignant Glioma Surgery: A Technical Note. World Neurosurgery, 2014, 82, e277-e279.	0.7	48
22	Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-¹⁸F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging. Molecular Imaging, 2013, 12, 7290.2013.00051.	0.7	38
23	Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. Journal of Neurosurgery, 2006, 105, 41-50.	0.9	35
24	Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. Neuro-Oncology, 2019, 21, 1331-1338.	0.6	31
25	The impact of cerebral metastases growth pattern on neurosurgical treatment. Neurosurgical Review, 2018, 41, 77-86.	1.2	27
26	A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials, 2018, 19, 293.	0.7	27
27	Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging. Journal of Neuro-Oncology, 2018, 139, 699-711.	1.4	26
28	Is 5-ALA fluorescence of cerebral metastases a prognostic factor for local recurrence and overall survival?. Journal of Neuro-Oncology, 2019, 141, 547-553.	1.4	26
29	Early treatment response assessment using ¹⁸F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254243.	2.8	25
30	Various shades of redâ€”a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery. Neurosurgical Review, 2018, 41, 3-18.	1.2	24
31	Clinical value of O-(2-[18F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma. Neurosurgical Focus, 2013, 34, E3.	1.0	23
32	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 306.	0.6	22
33	Training for brain tumour resection: a realistic model with easy accessibility. Acta Neurochirurgica, 2015, 157, 1975-1981.	0.9	19
34	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-l-tyrosine PET. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1486-1495.	3.3	16
35	DOSE-RELATED EFFICACY OF A CONTINUOUS INTRACISTERNAL NIMODIPINE TREATMENT ON CEREBRAL VASOSPASM IN THE RAT DOUBLE SUBARACHNOID HEMORRHAGE MODEL. Neurosurgery, 2009, 64, 1155-1161.	0.6	15
36	Impact of distress screening algorithm for psycho-oncological needs in neurosurgical patients. Oncotarget, 2018, 9, 31650-31663.	0.8	15

#	Article	IF	Citations
37	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1626-1635.	3.3	14
38	Correlation of psychooncological distress- screening and quality of life assessment in neurosurgical patients. Oncotarget, 2017, 8, 111396-111404.	0.8	14
39	Is the Intensity of 5-Aminolevulinic Acidâ€“Derived Fluorescence Related to the Light Source?. World Neurosurgery, 2019, 131, e271-e276.	0.7	12
40	Risk factors for in-brain local progression in elderly patients after resection of cerebral metastases. Scientific Reports, 2019, 9, 7431.	1.6	12
41	Predictors for a further local in-brain progression after re-craniotomy of locally recurrent cerebral metastases. Neurosurgical Review, 2018, 41, 813-823.	1.2	11
42	Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. British Journal of Neurosurgery, 2019, , 1-7.	0.4	11
43	5-ALAâ^'Induced Fluorescence in Leptomeningeal Dissemination of Spinal Malignant Glioma. World Neurosurgery, 2018, 110, 345-348.	0.7	10
44	Flare Phenomenon in O-(2-18F-Fluoroethyl)-l-Tyrosine PET After Resection of Gliomas. Journal of Nuclear Medicine, 2020, 61, 1294-1299.	2.8	10
45	Quantification of ALA-fluorescence induced by a modified commercially available head lamp and a surgical microscope. Neurosurgical Review, 2018, 41, 1079-1083.	1.2	9
46	Quantification of PpIX-fluorescence of cerebral metastases: a pilot study. Clinical and Experimental Metastasis, 2019, 36, 467-475.	1.7	9
47	Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. Scientific Reports, 2021, 11, 20828.	1.6	9
48	Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2015, 76, 298-302.	0.4	8
49	The use ofO-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. Neuro-Oncology, 2016, 19, now243.	0.6	8
50	Space-Occupying Tumor Bed Cysts as a Complication of Modern Treatment for High-Grade Glioma. World Neurosurgery, 2017, 104, 509-515.	0.7	8
51	Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. Journal of Cancer Research and Clinical Oncology, 2021, 147, 253-262.	1.2	8
52	Psychooncological distress in low-grade glioma patientsâ€”a monocentric study. Acta Neurochirurgica, 2022, 164, 713-722.	0.9	8
53	Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum JÃ¼lich Experience. Cancers, 2022, 14, 3336.	1.7	8
54	Treatment-Related Uptake of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-[Methyl-³H]-Methionine After Tumor Resection in Rat Glioma Models. Journal of Nuclear Medicine, 2019, 60, 1373-1379.	2.8	7

#	Article	IF	Citations
55	Is it all a matter of size? Impact of maximization of surgical resection in cerebral tumors. Neurosurgical Review, 2019, 42, 835-842.	1.2	7
56	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. Journal of Neurosurgery, 2022, 137, 914-923.	0.9	7
57	Proposed definition of competencies for surgical neuro-oncology training. Journal of Neuro-Oncology, 2021, 153, 121-131.	1.4	6
58	Case report: extracranial metastasis from gliosarcoma â€“ the influence of immune system. British Journal of Neurosurgery, 2011, 25, 286-288.	0.4	5
59	Glioma patients in outpatient careâ€”optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial. Trials, 2020, 21, 434.	0.7	5
60	Determination of optimal time window for cortical mapping in awake craniotomy: assessment of intraoperative reaction speed. Neurosurgical Review, 2020, 43, 633-642.	1.2	4
61	Positron-Emission-Tomography in Diffuse Low-Grade Gliomas. , 2017, , 263-286.		4
62	Impact of Anticipated Awake Surgery on Psychooncological Distress in Brain Tumor Patients. Frontiers in Oncology, 2021, 11, 795247.	1.3	4
63	Symptomatic communicating hydrocephalus in a contemporary cohort of high grade glioma patients. British Journal of Neurosurgery, 2018, 32, 68-72.	0.4	3
64	5-ALA fluorescence behavior of cerebral infectious and inflammatory disease. Neurosurgical Review, 2018, 41, 365-369.	1.2	3
65	fMRI Resting-State Connectivity between Language and Nonlanguage Areas as Defined by Intraoperative Electrocortical Stimulation in Low-Grade Glioma Patients. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2021, 82, 357-363.	0.4	2
66	Assessment Practice of Patient-Centered Outcomes in Surgical Neuro-Oncology: Survey-Based Recommendations for Clinical Routine. Frontiers in Oncology, 2021, 11, 702017.	1.3	2
67	Would they do it again? Final treatment decisions in malignant brain tumour patientsâ€”a caregiverâ€™s perspective. Supportive Care in Cancer, 2022, 30, 3985-3993.	1.0	2
68	Reply: Discriminating Ability of ¹⁸F-FET PET for Several Cerebral Neoplastic Lesions. Journal of Nuclear Medicine, 2014, 55, 176.2-176.	2.8	1
69	Extensive Craniocervical Abscess after Transoral Ganglionic Local Opioid Analgesia at the Superior Cervical Ganglion for Atypical Trigeminal Neuralgia: Report of a Severely Complicated Case. Case Reports in Medicine, 2018, 2018, 1-4.	0.3	1
70	Letter to the Editor Regarding â€œA Novel Wavelength-Specific Blue Light-Emitting Headlamp for 5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastomaâ€• World Neurosurgery, 2020, 133, 436-437.	0.7	1
71	Association between health insurance status and malignant glioma. Neuro-Oncology Practice, 2020, 7, 531-540.	1.0	1
72	The impact of preoperative MRI-based apparent diffusion coefficients on local recurrence and outcome in patients with cerebral metastases. British Journal of Neurosurgery, 2020, , 1-8.	0.4	0

#	Article	IF	Citations
73	Surgical Resection Techniques of Central Area Gliomas. , 2019, , 225-237.		0
74	Metastatic Tumors. , 2020, , 177-182.		0
75	Synthetic vascular grafts as a new treatment option for space-occupying tumor bed cysts. Acta Neurochirurgica, 2022, , 1.	0.9	0